Search Results
Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer
Dr. Willmott on Mechanisms of Resistance in Ovarian Cancer
Maintenance Olaparib Following Platinum-Based Chemotherapy for Newly Diagnosed Ovarian Cancer
Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer
Ovarian Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the C...
Clinical Investigators Provide Perspectives on Cases of Patients with Ovarian and Endometrial Cancer
Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-...
How PARP Inhibitors Can Increase Response to Immunotherapy